Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
110.3 USD | -0.40% | +1.84% | -10.32% |
09:54am | Jazz Pharmaceuticals Q1 Adjusted Earnings Decline, Revenue Rises; Reaffirms 2024 Outlook | MT |
May. 01 | (JAZZ) JAZZ PHARMACEUTICALS Forecasts Fiscal Year 2024 EPS Range $18.15 - $19.35 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.32% | 6.88B | |
+33.25% | 699B | |
+26.59% | 571B | |
-3.55% | 364B | |
+18.16% | 326B | |
+4.36% | 286B | |
+15.40% | 236B | |
+5.22% | 198B | |
-9.98% | 194B | |
-3.69% | 149B |
- Stock Market
- Equities
- JAZZ Stock
- News Jazz Pharmaceuticals plc
- RBC Raises Price Target on Jazz Pharmaceuticals to $195 From $191, Keeps Outperform Rating